Xenon grants 28,350 awards as Xenon Pharmaceuticals stock is valued at USD 3.3 billion

Published on 10/15/2026 at 13:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA filing supports epilepsy use after a psychiatry pause. Xenon Pharmaceuticals stock costs EUR 30.10 on October 15, 2026, with USD 3.3 billion value.

Development and valuation milestones

Xenon granted 28,350 equity awards on October 2, 2026.
The azetukalner application covered focal seizures on September 17, 2026, supported by more than 1,500 patient-years of exposure.
Xenon Pharmaceuticals stock trades at EUR 30.10 at 1:42 p.m. CEST at Lang & Schwarz on October 15, 2026.

XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals (CA98420N1050) announced equity inducement grants covering 28,350 awards on October 2, 2026. The disclosure adds hiring activity to a pipeline story centered on azetukalner, the company's lead neuroscience program.

October grants show continued hiring

According to BioSpace, the October 2 package consisted of 17,850 share options and 10,500 restricted share units for eight new non-officer employees. The options carried an exercise price of USD 38.93, equal to the common-stock closing price on October 1, 2026.

What does the epilepsy filing mean?

Xenon Pharmaceuticals submitted an application to the U.S. Food and Drug Administration for azetukalner in focal seizures on September 17, 2026. The filing was based on phase 2b and phase 3 studies, with more than 1,500 patient-years of exposure across the epilepsy program, while new enrollment in major depressive disorder and bipolar depression studies was paused after neuropsychiatric adverse events.

Three milestones shape the story

On August 6, 2026, Xenon reported adjusted earnings per share of USD -1.11 for the second quarter, compared with a USD -1.16 consensus estimate, according to Transcript Daily. The September 17 FDA filing followed, and the October 2 grants were the latest dated corporate disclosure.

Next clinical milestone

The company expects topline data from the X-NOVA2 major depressive disorder study in the first quarter of 2027, according to the September 17 release. That timing places the epilepsy regulatory path and the psychiatry readout on separate development tracks.

Stock valuation stays central

Xenon Pharmaceuticals has a USD 3.3 billion market capitalization as of October 14, 2026, while its primary listing is Nasdaq under ticker XENE. The company is classified in healthcare biotechnology and remains focused on drug discovery, clinical development, and commercialization of neurological therapies.

Xenon Pharmaceuticals was trading at EUR 30.10 at Lang & Schwarz on October 15, 2026 at 1:42 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Xenon Pharmaceuticals stock.